$MLTX MoonLake Immunotherapeutics lost nearly 90% of its stock value in one day after clinical trial results for its flagship nanobody drug disappointed investors. In this episode of Sue Wall Street, we dissect the class action lawsuit accusing MoonLake of hyping unproven biotech claims and misleading the market. If you follow biotech stocks, clinical trial risk, or Wall Street spin, don’t miss this one.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
